Sorafenib (Nexavar®) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia

✍ Scribed by N.N. Safaian; A. Czibere; I. Bruns; R. Fenk; P. Reinecke; A. Dienst; R. Haas; G. Kobbe

• Publisher: Elsevier Science
• Year: 2009
• Tongue: English
• Weight: 559 KB
• Volume: 33
• Category: Article
• ISSN: 0145-2126
• DOI: 10.1016/j.leukres.2008.04.017